Institutional shares held 93.6 Million
425K calls
309K puts
Total value of holdings $2.02B
$9.14M calls
$6.65M puts
Market Cap $1.52B
70,354,600 Shares Out.
Institutional ownership 133.0%
# of Institutions 255


Latest Institutional Activity in BEAM

Top Purchases

Q2 2025
Peregrine Investment Management Inc Shares Held: 264K ($5.69M)
Q2 2025
Steel Peak Wealth Management LLC Shares Held: 23K ($495K)
Q2 2025
Mirae Asset Global Investments Co., Ltd. Shares Held: 3.88K ($83.7K)
Q2 2025
Fortitude Family Office, LLC Shares Held: 31 ($668)
Q2 2025
Fifth Third Bancorp Shares Held: 26 ($560)

Top Sells

Q2 2025
Klp Kapitalforvaltning As Shares Held: 17.5K ($377K)
Q2 2025
Gamma Investing LLC Shares Held: 695 ($15K)
Q2 2025
Versant Capital Management, Inc Shares Held: 200 ($4.31K)
Q2 2025
Signaturefd, LLC Shares Held: 25 ($539)
Q2 2025
Org Partners LLC Shares Held: 30 ($646)

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


Insider Transactions at BEAM

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
358K Shares
From 8 Insiders
Grant, award, or other acquisition 253K shares
Exercise of conversion of derivative security 105K shares
Sell / Disposition
290K Shares
From 5 Insiders
Open market or private sale 290K shares

Track Institutional and Insider Activities on BEAM

Follow Beam Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BEAM shares.

Notify only if

Insider Trading

Get notified when an Beam Therapeutics Inc. insider buys or sells BEAM shares.

Notify only if

News

Receive news related to Beam Therapeutics Inc.

Track Activities on BEAM